Drug Device Combination Products Market to Reflect a Significant CAGR of 7.9% During 2013 - 2019
According to the research study, in 2012, the global drug device combination products market was worth US$66 bn and is anticipated to reach US$115 bn by the end of 2019, exhibiting a 7.9% CAGR between 2013 and 2019. The research report has made use of graphics, tables, and charts to present the historical data as well as forecast figures of the market. The report has also included inputs and recommendations from industry experts to help the existing as well as new players in designing their business strategies.
Read Report Overview @ https://www.transparencymarketresearch.com/drug-device-combination.html
The global market for drug device combination products is anticipated to grow substantially throughout the forecast period due to various factors such as government and NGO initiatives for encouraging drug delivery implants, increasing demand for minimally invasive surgeries, and rising number of interventional cardiologists. Moreover, advanced technologies, such as implants with drugs, help in pain relief, lowering morbidity, and quicker healing. Hence, these are anticipated to fuel the global drug device combination products market in the forecast period. On the other hand, recall of products due to their severe side effects is one of the major factors that is projected to hamper the growth of this market in the next few years.
According to type, the global market for drug device combination products is divided into transdermal patches, drug eluting stents, inhalers, orthopedic combination products, infusion pumps, photosensitizers, wound care combination products, and other products. A detailed analysis of the different types of drug device combination products has been included in the report coupled with their individual market share and revenue for the forecast period from 2013 to 2019.
Geographically, the global market for drug device combination products market has been segmented into North America, Europe, Asia Pacific, and Rest of the World. Among these regions, in terms of revenue, the global drug device combination products market is led by North America. Nevertheless, Asia Pacific is expected to witness high growth due to the growing prevalence of diabetes, cardiovascular diseases, and obesity, making it the most lucrative market in the coming years.
The research report has further presented the competitive landscape of the global drug device combination products market. The vendor analysis includes company details, contact information, business strategies, financial overview, SWOT analysis, and the recent developments. Some of the prominent players operating in global drug device combination products market are Pinnacle Biologics, Inc., W. L. Gore & Associates, Inc., Ethicon, Inc., Stryker Corporation, C.R. Bard, Inc., CareFusion Corporation, Medline Industries, Inc., Covidien PLC, Mylan, Inc., Terumo Corporation, and Medtronic, Inc.
Request Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1534
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.
Transparency Market Research
90 State Street,
Albany NY - 12207
USA - Canada Toll Free: 866-552-3453
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Drug Device Combination Products Market to Reflect a Significant CAGR of 7.9% During 2013 - 2019 here
News-ID: 848262 • Views: 126
More Releases from Transparency Market Research
Impact of Outbreak of COVID-19 on Medical Education Market : Global Industry Ana …
Transparency Market Research (TMR) has published a new report on the medical education market for the period of 2019–2027. According to the report, the global medical education market was valued at nearly US$ 31 Bn in 2018, and is projected to expand at a CAGR of more than 4% from 2019 to 2027. Rise in the number of medical schools and increase in cost of medical education are the
Healthcare BI Platform Market Companies Analysis, Advancement and Precise Outloo …
In an intensely competitive healthcare business intelligence (BI) platform market, large players are aggressively focused on expanding their geographical outreach, says Transparency Market Research (TMR) in a new market intelligence report. These large players are leveraging the cloud business model to provide healthcare BI solutions that can be accessed irrespective of location. Apart from this, savvy players are entering into partnerships with hospital groups and healthcare bodies to integrate healthcare BI
Substance Abuse Treatment Market News Research Report 2024
A recent report by Transparency Market Research on the substance abuse treatment market in the U.S. states that the competitive landscape is highly fragmented. This is because around 242 companies compete against one another in it. This also makes overall competition stiff. Some of the companies that have beat competition to emerge as leading players in the market are Pfizer Inc., Alkermes Plc, GlaxoSmithKline Plc., and Purdue Pharma LP. Their
Clinical Oncology Next Generation Sequencing Market is Thriving Worldwide By Siz …
Clinical Oncology Next Generation Sequencing: Introduction Next generation sequencing for tumor and germline DNA is required for oncology screening for therapeutic application. Rise in burden of cancer increases the need for early detection of the condition to carry out the generate target therapy. Companies are investing to develop technologically advanced devices/solutions for precision detection. In 2012, Oxford Nanopore had launched the GridION sequencing platform, which can sequence a human genome in 15
More Releases for Drug
Biologics Drug Discovery Market
2019-2025 Biologics Drug Discovery Market Report with Depth Analysis The biologics drug discovery involves target identification, hit-to-lead stage, lead identification and optimization. The report presents a comprehensive overview, market size, shares, and growth opportunities of Biologics Drug Discovery market by product type, application, key manufacturers and key regions. Request For Free report Sample -https://www.reportsmonitor.com/request_sample/306320 Scope of the Report: Furthermore, Biologics Drug Discovery Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers or
Opioid Antagonist Drug Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global Opioid Antagonist Drug Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential
Drug and cosmetics
Drug and Cosmetics Conferences regards each one of the individuals to go to the On “Drug and Cosmetics” amidst October 17-October 18, 2018 in Toronto, Canada which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops. Drug and Cosmetics Congress is one of the meetings and conferences which will be visited by all the prestigious cosmetologists, Scientists, fiery inspectors, postgraduates, affiliations, business meanders under a solitary rooftop. DRug and cosmetics BLESSY MATHEW Program
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: firstname.lastname@example.org or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: email@example.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning